ONCY Stock — Oncolytics Biotech Inc.: Cash, EV, Pipeline

Share price

$0.77

Market cap

$98.2M

Cash

$4.1M

Enterprise value

$94.1M

Balance sheet

Cash	$4.1M
Debt	$0.0M
Net cash	$4.1M
Enterprise value	$94.1M
Basic shares	124.6M shares
Fully diluted shares	168.1M shares
Fully diluted market cap	$129.4M
Cash per share	$0.03

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ONCY daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 10 - Oct 22	Pelareorep	Phase 1/2	Anal Cancer Metastatic; Squamous Cell Carcinoma of the Anus Stage Unspecified; Pancreatic Cancer Metastatic	—
Oct 11 - Nov 22	Bevacizumab	Phase 2	Ras-mutated Metastatic Colorectal Cancer; mCRC; MSS Metastatic Colorectal Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Pelareorep

Phase 2 · Active Modality: Immunotherapy (intravenous reovirus isolate)

Partnerships Adlai Nortye Biopharma: exclusive development/commercialization rights in China, Hong Kong, Macau, Singapore, South Korea, Taiwan. PanCAN: Therapeutic Accelerator Award (up to $5M) funding a pelareorep pancreatic cancer trial. National Research Council of Canada: manufacturing collaboration.

Indications

2L KRAS-mutant MSS metastatic colorectal cancer (Phase 2)
2L+ squamous cell carcinoma of the anal canal (Phase 2)
Metastatic pancreatic ductal adenocarcinoma (Stage not disclosed)

Catalysts

— 2026 (fall/winter)

Status note Lead and only clinical asset. REO 033 randomized Phase 2 in 2L RAS-mutant MSS mCRC launched Mar 2026 (first site early Apr 2026); FDA Fast Track granted Q1 2026. GOBLET Cohort 4 in relapsed unresectable SCAC completed enrollment; Type C FDA meeting (Apr 2026) held on pivotal 2L+ SCAC trial; FDA Fast Track granted Jul 2026. Evaluating strategic options for registrational mPDAC program.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Bevacizumab
Lead indication	Ras-mutated Metastatic Colorectal Cancer
Lead phase	Phase 2
Active trials	3
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07446322	Phase 2	Recruiting	Sponsor	Oncolytics Biotech	—	Ras-mutated Metastatic Colorectal Cancer; mCRC; MSS Metastatic Colorectal Cancer	—
NCT04215146	Phase 2	Active, not recruiting	Sponsor	Oncolytics Biotech	—	Breast Cancer Metastatic	—
NCT07280377	Phase 1/2	Active, not recruiting	Sponsor	Oncolytics Biotech	—	Anal Cancer Metastatic; Squamous Cell Carcinoma of the Anus Stage Unspecified; Pancreatic Cancer Metastatic	—
NCT04445844	Phase 2	Active, not recruiting	Collaborator	Mridula George, MD	—	Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Oncolytics Biotech on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ONCY — Oncolytics Biotech Inc.